Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam

por Kletzl, Heidemarie, Ajmi, Hassan, Antys, Izabela, Heinig, Katja, Jaber, Birgit, Marbury, Thomas C., Young, Annie, Günther, Andreas
Publicado 2022

Model‐Based Drug–Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy

por Cleary, Yumi, Gertz, Michael, Grimsey, Paul, Günther, Andreas, Heinig, Katja, Ogungbenro, Kayode, Aarons, Leon, Galetin, Aleksandra, Kletzl, Heidemarie
Publicado 2021

Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug–Drug Interactions in Children

por Cleary, Yumi, Kletzl, Heidemarie, Grimsey, Paul, Heinig, Katja, Ogungbenro, Kayode, Silber Baumann, Hanna Elisabeth, Frey, Nicolas, Aarons, Leon, Galetin, Aleksandra, Gertz, Michael
Publicado 2023

Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO

por Gibiansky, Ekaterina, Petry, Claire, Mercier, Francois, Günther, Andreas, Herman, Ann, Kappos, Ludwig, Hauser, Stephen, Yamamoto, Yumi, Wang, Qing, Model, Fabian, Kletzl, Heidemarie
Publicado 2020

Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis

por Hauser, Stephen L., Bar-Or, Amit, Weber, Martin S., Kletzl, Heidemarie, Günther, Andreas, Manfrini, Marianna, Model, Fabian, Mercier, Francois, Petry, Claire, Wing, Qing, Koendgen, Harold, Smith, Terence, Kappos, Ludwig
Publicado 2023

A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder

por Umbricht, Daniel, del Valle Rubido, Marta, Hollander, Eric, McCracken, James T, Shic, Frederick, Scahill, Lawrence, Noeldeke, Jana, Boak, Lauren, Khwaja, Omar, Squassante, Lisa, Grundschober, Christophe, Kletzl, Heidemarie, Fontoura, Paulo
Publicado 2017

Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study

por Chiriboga, Claudia A., Bruno, Claudio, Duong, Tina, Fischer, Dirk, Mercuri, Eugenio, Kirschner, Janbernd, Kostera-Pruszczyk, Anna, Jaber, Birgit, Gorni, Ksenija, Kletzl, Heidemarie, Carruthers, Imogen, Martin, Carmen, Warren, Francis, Scalco, Renata S., Wagner, Kathryn R., Muntoni, Francesco
Publicado 2023

Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study

por Chiriboga, Claudia A., Bruno, Claudio, Duong, Tina, Fischer, Dirk, Mercuri, Eugenio, Kirschner, Janbernd, Kostera-Pruszczyk, Anna, Jaber, Birgit, Gorni, Ksenija, Kletzl, Heidemarie, Carruthers, Imogen, Martin, Carmen, Warren, Francis, Scalco, Renata S., Wagner, Kathryn R., Muntoni, Francesco
Publicado 2023

Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA)

por Oskoui, Maryam, Day, John W., Deconinck, Nicolas, Mazzone, Elena S., Nascimento, Andres, Saito, Kayoko, Vuillerot, Carole, Baranello, Giovanni, Goemans, Nathalie, Kirschner, Janbernd, Kostera-Pruszczyk, Anna, Servais, Laurent, Papp, Gergely, Gorni, Ksenija, Kletzl, Heidemarie, Martin, Carmen, McIver, Tammy, Scalco, Renata S., Staunton, Hannah, Yeung, Wai Yin, Fontoura, Paulo, Mercuri, Eugenio
Publicado 2023

Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)

por Oskoui, Maryam, Day, John W., Deconinck, Nicolas, Mazzone, Elena S., Nascimento, Andres, Saito, Kayoko, Vuillerot, Carole, Baranello, Giovanni, Goemans, Nathalie, Kirschner, Janbernd, Kostera-Pruszczyk, Anna, Servais, Laurent, Papp, Gergely, Gorni, Ksenija, Kletzl, Heidemarie, Martin, Carmen, McIver, Tammy, Scalco, Renata S., Staunton, Hannah, Yeung, Wai Yin, Fontoura, Paulo, Mercuri, Eugenio
Publicado 2023